ACRI Signs Non-Exclusive License Agreement with BioVendor for liquid biopsy enabling technology
(Moncton, Canada) - March 15th,
– The Atlantic Cancer Research Institute (ACRI) is pleased to announce an
agreement with BioVendor – Laboratorní medicína a.s. to license its patented
intellectual property for the use of the Vn96 synthetic peptide in liquid
biopsy applications. The agreement gives BioVendor non-exclusive rights to use
the Vn96 peptide for the isolation of extracellular vesicles for the diagnosis
of diseases, such as cancer.
Extracellular vesicles (EVs), which include exosomes, are small cell-derived particles that are present within body fluids such as plasma and urine. EVs contain a sample of the DNA, RNA, protein, lipids and metabolites found within the cells from which they are derived and therefore are a valuable source of biomarkers that reflect the real-time state of both healthy and diseased cells. The Vn96 synthetic peptide, developed by ACRI and New England Peptide Inc. (Gardner, MA), is recognized as one of the leading technologies that enables EV capture from body fluids. Liquid biopsy is a precision medicine technology that offers physicians and health professionals the ability to test a patient in real time to obtain multi-parametric biomarker information and guide therapeutic choices. The Vn96 peptide enables liquid biopsy by providing a fast and reproducible method for the isolation of EVs, and the information that they contain, which is clinically amenable and requires minimal specialized equipment.
About BioVendor BioVendor - Laboratorni medicina a.s. was established in the Czech Republic in 1992 as a distributor of clinical chemistry and life science laboratory products. The Research and Diagnostic Products division is an innovative biotechnology company focused on the development and manufacture of in vitro diagnostics and for-research-use immunoassays, recombinant proteins and antibodies. BioVendor’s R&D assays for in vitro diagnostics are aimed at rapidly growing fields of interest within the international research and diagnostic community, such as the oncology and liquid biopsy markets.
About ACRI The Atlantic Cancer Research Institute is a private, not-for-profit research organization created in 1998 and located at the Dr. Georges-L.-Dumont University Hospital Centre in Moncton, NB, Canada. Unique to the region and operating a modern biomedical research laboratory, this entrepreneurial team is striving to innovate by accelerating its understanding of cancer, thus paving the way to better diagnosis, more accurate patient stratification and drug discovery.
Quotes “The license agreement is a very important piece in our strategy to bring innovative immunoassays that target miRNA as clinically valuable biomarkers.”- Viktor Růžička, M.D., CEO of BioVendor – Laboratorní medicína a.s.
“We are very pleased to conclude this licensing agreement with an innovative company like BioVendor. We are confident that our extracellular vesicle isolation technology will be able to enhance their diagnostic and liquid biopsy products.” – Dr. Rodney Ouellette, President and Scientific Director of ACRI
For additional information, please contact:
Remi Richard, Business Development Agent
Atlantic Cancer Research Institute
All articlesACRI Signs Non-Exclusive License Agreement with BioVendor for liquid biopsy enabling technology
The Globe and Mail: Canada to make skilled-worker permits easier to get in wake of U.S. delays
Oulton College launches Free Academic Upgrading
GLOBAL COMMERCE INSIDER: Company found a way to make glass bottles and jars last longer
UNB’s Ali Ghorbani appointed Canada Research Chair in Cybersecurity
New Brunswick companies to receive support to grow in export markets
Apply to participate - Trade Mission to New York City, March 20 - 22, 2017
New Brunswick tech companies sharpen sales and marketing skills at INBOUND conference
Venn contributes to Global Skills Visa Proposal
Government appoints new chief entrepreneur in residence